NVO

Announcements

Nothing here yet

Daily updates

• Novo Nordisk agreed to pay up to $2.6 billion for rights to an oral obesity drug developed by China’s Hengrui Pharma that could be dosed once weekly.Sep 30, 2026

FDA designations

Nothing here yet

News

• Novo Nordisk provides an update on the U.S. BLA for denecimigOct 4, 2026
• Novo Nordisk reports that Wegovy (semaglutide) normalized liver fat levels in 9 out of 10 adults with obesity and excess liver fat in EASD 2026 dataOct 1, 2026
• Metsera receives unsolicited proposal from Novo NordiskOct 30, 2025
• Wegovy® approved by FDA for treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosisAug 18, 2025